Diabetes mellitus and atrial fibrillation

Česká verzia

Authors: Ján Murín
Authors place of work: I. interná klinika LF UK a UNB, Nemocnica Staré Mesto, Bratislava
Published in the journal: Forum Diab 2022; 11(2): 76-81
Category:

Summary

Diabetes mellitus is one of the most common chronic medical diseases and is also a risk factor for the development of atrial fibrillation (AF). The presence of diabetes in patients with AF is associated with increased symptom burden and increased cardiovascular and cerebrovascular mortality. The pathophysiology of diabetes – related AF is not fully understood, but is related to structural, electrical, electro-mechanical and autonomic remodeling. This article reviews the complex interaction between diabetes and AF, and also explores its effect on the prevention and treatment of AF.

Keywords:

atrial fibrillation – diabetes mellitus – pathophysiology of atrial fibrillation in diabetes – prevention/ treatment of atrial fibrillation in diabetes

Zdroje

1. Národné centrum zdravotníckych informácií. Výkaz o činnosti diabetologických ambulancií (MZ SR) za roky 2013–2020. Dostupné z WWW: <https://www.nczisk.sk/Statisticke_vystupy/Tematicke_statisticke_ vystupy/Diabetologia/Pages/default.aspx>.

2. Benjamin EJ, Muntner P, Alonso A et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2019; 139(10): e56-e528. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000000659>.

3. Colilla S, Crow A, Petkun W et al. Estimates of current and future incidence and prevalence of atrial fibrilation in the U.S. adult population. Am J Cardiol 2013; 112(8): 1142–1147. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2013.05.063>.

4. Echouffo-Tcheugui JB, Shrader P, Thomas L et al. Care patterns and outcomes in atrial fibrillation patients with and without diabetes: ORBIT- AF Registry. J Am Coll Cardiol 2017; 70(11): 1325–1335. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2017.07.755>.

5. Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994; 271(11): 840–844.

6. Huxley RR, Filion KB, Konety S et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011; 108(1): 56–62. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2011.03.004>.

7. Dublin S, Glazer NL, Smith NL et al. Diabetes mellitus, glycemic control and risk of atrial fibrillation. J Gen Intern Med 2010; 25(8): 853–858. Dostupné z DOI: <http://dx.doi.org/10.1007/s11606–010–1340-y>.

8. Du X, Ninomiya T, de Galan B et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009; 30(9): 1128–1135. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehp055>.

9. Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol 2016; 90: 84–93. Dostupné z DOI: <http://dx.doi.org/10.1016/j.yjmcc.2015.12.011>.

10. Liu C, Fu H, Li J et al. Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits. Anadolu Kardiyol Dergisi 2012; 12(7): 543–550. Dostupné z DOI: <http://dx.doi.org/10.5152/akd.2012.188>.

11. Kato T, Yamashita T, Sekiguchi A et al. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. J Cardiovasc Electrophysiol 2008; 19(4): 415–420. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1540–8167.2007.01037.x>.

12. Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease: Diabetologia 2018; 61(1): 21–28. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–017–4390–4>.

13. Tiwari S, Schirmer H, Jacobsen BK et al. Association between diastolic dysfunction and future atrial fibrillation in the Tromsø Study from 1994 to 2010. Heart 2015; 101(16): 1302–1308. Dostupné z DOI: <http://dx.doi.org/10.1136/heartjnl-2015–307438>.

14. Watanabe M, Yokoshiki H, Mitsuyama H et al. Conduction and refractory disorders in the diabetic atrium. Am J Physiol Heart Circ Physiol 2012; 303(1): H86-H95. Dostupné z DOI: <http://dx.doi.org/10.1152/ajpheart.00010.2012>.

15. Chao TF, Suenari K, Chang S et al. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. Am J Cardiol 2010; 106(11): 1615–1620. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2010.07.038>.

16. Fu H, Liu C, Li J et al. Impaired atrial electromechanical function and atrial fibrillation promotion in alloxan-induced diabetic rabbits. Cardiol J 2013; 20(1): 59–67. Dostupné z DOI: <http://dx.doi.org/10.5603/CJ.2013.0010>.

17. Ayhan S, Ozturk S, Alcelik A et al. Atrial conduction time and atrial mechanical function in patients with impaired fasting glucose. J Interv Card Electrophysiol 2012; 35(3): 247–252. Dostupné z DOI: <http://dx.doi.org/10.1007/s10840–012–9722–1>.

18. Demir K, Avci A, Kaya Z et al. Assesssment of atrial electromechanical delay and P-wave dispersion in patients with type 2 diabetes mellitus. J Cardiol 2016; 67(4): 378–383. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jjcc.2015.06.003>.

19. De Vos CB, Weijs B, Crijns HJGM et al. Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart 2009; 95(10): 835–840. Dostupné z DOI: <http://dx.doi.org/10.1136/hrt.2008.148528>.

20. Kuehl M, Stevens MJ. Cardiovascular autonomic neuropathies as complications of diabetes mellitus. Nat Rev Endocrinol 2012; 8(7): 405–416. Dostupné z DOI: <http://dx.doi.org/10.1038/nrendo.2012.21>.

21. Otake H, Suzuki H, Honda T et al. Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. Int Heart J 2009; 50(5): 627–641. Dostupnéz DOI: <http://dx.doi.org/10.1536/ihj.50.627>.

22. Benichou T, Pereira B, Mermillod M et al. Heart rate variability in type 2 diabetes mellitus: a systematic review and meta-analysis. PloS One 2018; 13(4): e0195166. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0195166>.

23. Rizzo MR, Sasso FC, Marfella R et al. Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes. J Diabetes Complications 2015; 29(1): 88–92. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jdiacomp.2014.09.002>.

24. Anderson EJ, Kypson AP, Rodriquez E et al. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 2009; 54(20): 1891–1898. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2009.07.031>.

25. Ziolo MT, Mohler PJ. Defining the role of oxidative stress in atrial fibrillation and diabetes. J Cardiovasc Electrophysiol 2015; 26(2): 223–225. Dostupné z DOI: <http://dx.doi.org/10.1111/jce.12560>.

26. Faria A, Persaud SJ. Cardiac oxidative stress in diabetes: mechanisms and therapeutic potential. Pharmacol Ther 2017; 172: 50–62. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pharmthera.2016.11.013>.

27. Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012; 60(22): 2263–2270. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.04.063>.

28. Fatemi O, Yuriditsky E, Tsioufis C et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the action to control cadiovascular risk in diabetes study). Am J Cardiol 2014; 114(8): 1217–1222. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2014.07.045>.,

29. Gu J, Fan YQ, Zhang JF et al. Impact of long-term glycemic variability on development of atrial fibrillation in type 2 diabetic patients. Anatol J Cardiol 2017; 18(6): 410–416. Dostupné z DOI: <http://dx.doi. org/10.14744/AnatolJCardiol.2017.7938>.

30. Hanefeld M, Frier BM, Pistrosch F. Hypoglycemia and cardiovascular risk: is there a major link? Diabetes Care 2016; 39(Suppl 2): S205-S209. Dostupné z DOI: <http://dx.doi.org/10.2337/dcS15–3014>.

31. Ko SH, Park YM, Yun JS et al. Severe hypoglycemia is a risk factor for atrial fibrillation in type 2 diabetes mellitus: nationwide population-based cohort study. J Diabetes Complications 2018; 32(2): 157–163. Dostupné z DOI: http://dx.doi.org/10.1016/j.jdiacomp.2017.09.009>.

32. Saito S, Teshima Y, Fukui A et al. Glucose fluctuations increase the incidence of atrial fibrillation in diabetic rats. Cardiovasc Res 2014; 104(1): 5–14. Dostupné z DOI: <http://dx.doi.org/10.1093/cvr/cvu176>.

33. Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. J Am Med Assoc 2006; 295(14): 1681–1687. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.295.14.1681>.

34. Chang SH, Wu LS, Chiou MJ et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol 2014; 13: 123–132. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–014–0123-x>.

35. Chao TF, Leu HB, Huang CC et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Int J Cardiol 2012; 156(2): 199–202. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2011.08.081>.

36. Chen HY, Yang FY, Jong GP et al. Antihyperglycemic drugs use and new-onset atrial fibrillation in elderly patients. Eur J Clin Invest 2017; 47(5): 388–393. Dostupné z DOI: <http://dx.doi.org/10.1111/eci.12754>.

37. Liou YS, Yang FY, Chen HY et al. Antihyperglycemic drugs use and new-onset atrial fibrillation: a population-based nested case control study. PloS One 2018; 13(8): e0197245. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0197245>.

38. Monami M, Nreu B, Scatena A et al. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and metaanalysis of randomised controlled trials. J Endocrinol Invest 2017; 40(11): 1251–1258. Dostupné z DOI: <http://dx.doi.org/10.1007/s40618–017–0698–7>.

39. Usman MS, Siddiqi TJ, Memon MM et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol 2018; 25(5): 495–502. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487318755531>.

40. Zhang Z, Zhang X, Korantzopoulos P et al. Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. BMC Cardiovasc Disord 2017; 17(1): 96. Dostupné z DOI: <http://dx.doi.org/10.1186/s12872–017–0531–4>.

41. Kume O, Takahshi N, Wakisaka O et al. Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhytm 2011; 8(2): 278–285. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hrthm.2010.10.029>.

42. Yu O, Azoulay L, Yin H et al. Sulfonylureas as initial treatment for type 2 diabetes and the risk of severe hypoglycemia. Am J Med 2018; 131(3): e11–317.e22. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2017.09.044>.

43. Gerstein H, Bosch J, Dagenais G et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367(4): 319–328. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1203858>.

44. Chang CY, Yeh YH, Chan YH et al. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. Cardiovasc Diabetol 2017; 16(1): 159. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–017–0640–5>.

45. White WB, Cannon CP, Heller SR et al. EXAMINE: alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369(14): 1327–1335. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1305889>.

46. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. SAVOR-TIMI Trial. N Engl J Med 2013; 369(14): 1317–1326. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1307684>.

47. Rosenstock J, Perkovic V, Johansen OE et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. JAMA 2019; 321(1): 69–79. <http://dx.doi.org/10.1001/jama.2018.18269>.

48. Holman RR, Bethel MA, Mentz RJ et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377(13): 1228–1239. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1612917>.

49. Hernandez AF, Green JB, Janmohamed S et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392(10157): 1519–1529. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)32261-X>.

50. Patti G, Cavallari I, Andreotti F et al. Prevention of atherothrombotic events in patients with diabetes mellitus. From antithrombotic therapies to new-gneration glucose-lowering drugs. Nat Rev Cardiol 2019; 16(2): 113–130. Dostupné z DOI: <http://dx.doi.org/10.1038/s41569–018–0080–2>.

51. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016; 50(5): e1-e88. Dostupné z DOI: <http://dx.doi.orgé10.1093/ejcts/ezw313>.

52. Itzhaki Ben Zadok O, Eisen A. Use of non-vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus. Diabet Med 2018; 35(5): 548–556. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.13600>.

53. Nelson WW, Chol JC, Vanderpoel J et al. Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation. Am J Cardiol 2013; 112(4): 509–512. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2013.04.013>.

54. Ashburner JM, Go AS, Chang Y et al. Effect of diabetes and glycemic control on ischemic stroke risk in AF patients, ATRIA study. J Am Coll Cardiol 2016; 67(3): 239–247. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2015.10.080>.

55. Patti G, Lucerna M,Cavallari I et al. Insulin-requiring versus noninsulin-requiring diabetes and thromboembolic risk in patients with atrial fibrillation: PREFER in AF. J Am Coll Cardiol 2017; 69(4): 409–419. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2016.10.069>.

56. Ito I, Hayashi Y, Kawai Y et al. Diabetes mellitus reduces the antiarrhythmic effect of ion channel bilockers. Anesth Analg 2006; 103(3): 545–550. Dostupné z DOI: <http://dx.doi.org/10.1213/01.ane.0000229709.29185.88>.

57. Scirica BM. Prevalence, incidence, and implications of silent myocardial infarctions in patients with diabetes mellitus. Circulation 2013; 127(9): 965–967. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.113.001180>.

58. Veglio M, Bruno G, Borra M et al. Prevalence of increased QT interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease: a population-based cohort. J Intern Med 2002; 251(4): 317–324. Dostupné z DOI: <http://dx.doi.org/10.1046/j.1365–2796.2002.00955.x>.

59. Soran H, Benerjee M, Mohamed JB et al. Risk factors for failure of direct current cardioversion in patients with type 2 diabetes mellitus and atrial fibrillation. Biomed Res Int 2018; 2018: 5936180. Dostupné z DOI: <http://dx.doi.org/10.1155/2018/5936180>.

60. Grönberg T, Hartikainen JEK, Nuotio I et al. Can we predict the failure of electrical cardioversion of acute atrial fibrillation? The FinCV study. Pacing Clin Electrophysiol 2015; 38(3): 368–375. Dostupné z DOI: <http://dx.doi.org/10.1111/pace.12561>.

61. Ebert M, Stegmann C, Kosluk J et al. Predictors, management and outcome of cardioversion failure early after atrial fibrillation ablation. Europace 2018; 20(9): 1428–1434. Dostupné z DOI: <http://dx.doi.org/10.1093/europace/eux327>.

62. Forleo GB, Mantica M, De Luca L et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 2009; 20(1): 22–28. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1540–8167.2008.01275.x>.

63. Tang RB, Dong JZ, Liu XP et al. Safety and efficacy of catheter ablation of atrial fibrillation in patients with diabetes mellitus-single center experience. J Interv Card Electrophysiol 2006; 17(1): 41–46. Dostupné z DOI: <http://dx.doi.org/10.1007/s10840–006–9049-x>.

64. Bogossian H, Frommeyer G, Brachmann J et al. Catheter ablation of atrial fibrillation and atrial flutter in patients with diabetes mellitus: who benefits and who does not? Data from the German ablation registry. Int J Cardiol 2016; 214: 25–30. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2016.03.069>.

65. Anselmino M, Matta M, D’Ascenzo F et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and meta-analysis. Europace 2015; 17(10): 1518–1525. Dostupné z DOI: <http://dx.doi.org/10.1093/europace/euv214>.